In a new osteoarthritis (OA) genome-wide meta-analysis that used data from the UK Biobank and the Arthritis Research UK Osteoarthritis Genetics (arcOGEN) consortium, which included ~17.5 million single-nucleotide variants in >450,000 individuals of European descent, 64 genome-wide-significant regions have been identified. This study adds 52 new loci to the list of 34 already-known disease-associated loci in OA, including 24 for OA at any site, 15 for hip OA, 7 for knee OA and 6 for hip and/or knee OA. Ten of the putative effector genes are targets of approved therapeutics or therapeutics in clinical trials.
References
Original article
Tachmazidou, I. et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat. Genet. 51, 230–236 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McHugh, J. OA genetic risk loci more than doubled. Nat Rev Rheumatol 15, 126 (2019). https://doi.org/10.1038/s41584-019-0179-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0179-9